<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> occurs frequently in patients with human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and acquired <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We determined the association between the clinical and histologic features of HIV-related <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>SUBJECTS AND METHODS: We reviewed the medical records of 291 patients with noncerebral HIV-related <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who had been treated in multicenter trials coordinated by the <z:chebi fb="98" ids="24433">Groupe</z:chebi> d'Etude des Lymphomes de l'Adulte between 1988 and 1997 </plain></SENT>
<SENT sid="3" pm="."><plain>This study was performed mainly before the availability of combination antiretroviral therapy </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The main histologic subtypes were <z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in 131 patients (45%), <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in 39 patients (13%), and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (including the classical form and the variant with plasmacytic differentiation) in 115 patients (40%) </plain></SENT>
<SENT sid="5" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was the most aggressive form, whereas <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> occurred in severely immunodeficient patients </plain></SENT>
<SENT sid="6" pm="."><plain>Two-year survival after enrollment was 15% in <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 32% in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and 31% in <z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (P = 0.006), but multivariate analysis did not confirm the independent prognostic value of histologic subtype </plain></SENT>
<SENT sid="7" pm="."><plain>Instead, five independent pretreatment factors increased the risk of mortality: age 40 years or older [relative risk (RR) = 1.5; 95% confidence interval (CI), 1.1 to 2.1; P = 0.005], elevated serum <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase level (RR = 1.5; 95% CI, 1.1 to 2.1; P = 0.02), having a diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> before <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (RR = 1.8; 95% CI, 1.2 to 2.6; P = 0.006), CD4(+) cell count less than 100 x 10(6)/L (RR = 1.8; 95% CI, 1.3 to 2.6; P = 0.0004), and impaired performance status (RR = 2.4; 95% CI, 1.7 to 3.4; P &lt;0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Several pretreatment characteristics of HIV-related <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were linked to the histologic form, but <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV disease</z:e> parameters other than those of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were the main determinants of outcome, so the histologic features of the <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were not associated with prognosis </plain></SENT>
</text></document>